VEEV — Veeva Systems Inc.

Sentiment is bullish after the late-August 2026 Q2 FY2027 beat: revenue +17.6% YoY to $928.0M, adjusted EPS ~$2.35 vs $2.10 expected, and operating income of $275.0M. Vault CRM has >150 live customers with >80% win rate, and investors are rewarding Veeva's AI monetization path (Falcon MLR). Analyst consensus is Buy with price targets mostly $285-$330. The 1-week -4.61% dip is minor against 3-month +64.47% and 6-month +46.69% gains.

Three-year trend is improving, not deteriorating. Revenue rose from $616.5M in Oct-2023 to $928.0M in Jul-2026; YoY growth accelerated from ~13.4% (Oct-2024) to 17.6% (Jul-2026). Operating margin expanded from ~20.8% to ~29.6%, and diluted EPS grew from $0.83 to $1.66. FCF is seasonally lumpy—Q1 FY2027 (Apr-2026) OCF was $1.127B—so the flat Q2 OCF YoY ($238.7M vs $238.4M) is billing timing, not a structural slowdown.

As of 2026-09-13, VEEV trades at $262.40. TTM P/E is 42.3 vs its 5-year average of 58.4, and P/S is 12.3 vs 14.0. Forward P/E on next-FY EPS of $9.235 is ~28.4x; PEG is 1.71. That is fair-to-modestly-cheap relative to its own history, but not an absolute bargain for ~17% revenue growth. The deterministic 'Cheap vs. its own history' label is supported, though the forward multiple already reflects solid execution.

The stock is pricing in continued mid-to-high-teens revenue growth and margin expansion. At $262.40, the market is paying ~28x next-FY EPS and ~11.5x next-FY revenue. If Veeva keeps beating and raising—especially on Vault CRM and Falcon AI monetization—earnings estimates can move higher and justify a re-rating toward the mid-$300s. If growth slips to low-teens or AI monetization stalls, the multiple has room to compress toward the low-$200s.

As of 2026-09-13, RSI is 56.91 (neutral, not overbought). Price is 0.39% above SMA20, 15.7% above SMA50, and 32.15% above SMA200—a strong uptrend but extended versus longer averages. 1-month +8.65%, 3-month +64.47%, 6-month +46.69%, but 1-week -4.61%. The trend favors holding, while new entry timing would be better on a pullback toward the SMA50 rather than chasing after a 64% three-month run.

• Resilient life sciences IT spend: pharma R&D and commercial compliance budgets are mission-critical and less discretionary than general enterprise software.
• AI/vertical software rotation: investors now favor secure, domain-specific AI agents like Veeva Falcon MLR over generic horizontal AI tools.
• Interest rate backdrop: lower rates would support long-duration software multiples; higher-for-longer rates would pressure VEEV's high absolute P/E.
• Sector rotation toward quality balance sheets: Veeva's ~$7B cash/investments and zero debt make it a defensive-quality software name.
• Regulatory/compliance complexity in life sciences: FDA and drug-pricing changes can increase demand for Veeva's systems of record even as customer budgets face scrutiny.

• Q3 FY2027 earnings in late November 2026: updated guidance, net retention, subscription revenue growth, and AI monetization metrics.
• Vault CRM migration progress: >150 live customers today; further adoption and post-Salesforce separation wins.
• Veeva Falcon MLR commercial rollout: early enterprise feedback and ROI-based pricing could drive new revenue.
• Analyst estimate revisions: consensus target is $290.50, high $330; continued beats could pull targets higher.

• Customer concentration in life sciences: pharma budget cuts, M&A consolidation, or pricing pressure could slow subscription growth.
• Competitive threat: Salesforce and other CRM/cloud vendors could slow Vault CRM migration or limit pricing power.
• Valuation risk: TTM P/E 42.3 and forward P/E 28.4 leave little room for growth disappointment; PEG 1.71 is not cheap.
• Execution risk in AI monetization: Falcon MLR and other AI products may take longer to scale or face adoption hurdles.
• Macro/rate risk: higher-for-longer interest rates could compress high-multiple software valuations.

Veeva is a high-quality, debt-free vertical software compounder with accelerating revenue (+17.6% YoY), expanding operating margins (~30%), and a pristine balance sheet. The stock trades below its 5-year average P/E and P/S, and Vault CRM migration plus AI monetization provide real optionality. That said, the forward P/E of ~28x and PEG of 1.7 mean it is fairly valued, not a steal, and the 64% three-month run raises near-term pullback risk. For long-term investors, the risk/reward is positive but not urgent; buy on weakness rather than chase.

Applied a 32x forward P/E to next-FY consensus EPS of $9.235, justified by Veeva's 17-18% revenue growth, ~30% operating margins, net-cash balance sheet, and current forward P/E of 28.4x versus a 5-year average TTM P/E of 58.4x. Cross-checked with 13x forward P/S on next-FY revenue of $3.69B, both approaches yield ~$295.